323 related articles for article (PubMed ID: 31932560)
21. Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial.
Liu X; Johnson M; Mardekian J; Phatak H; Thompson J; Cohen AT
J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26627879
[TBL] [Abstract][Full Text] [Related]
22. Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study.
Chao TF; Liu CJ; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Liao JN; Chung FP; Chen TJ; Lip GYH; Chen SA
Circulation; 2018 Jul; 138(1):37-47. PubMed ID: 29490992
[TBL] [Abstract][Full Text] [Related]
23. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
Cohen AT; Agnelli G; Buller HR; Gallus A; Raskob GE; Sanders P; Thompson J; Weitz JI
Thromb Haemost; 2019 Mar; 119(3):461-466. PubMed ID: 30650446
[TBL] [Abstract][Full Text] [Related]
24. Deep Vein Thrombosis and Pulmonary Embolism in the Apixaban Era: From Bench to Bedside.
Poredos P; Jezovnik MK
Curr Drug Targets; 2018; 19(6):577-580. PubMed ID: 25981607
[TBL] [Abstract][Full Text] [Related]
25. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y
J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review.
Adam SS; McDuffie JR; Ortel TL; Williams JW
Ann Intern Med; 2012 Dec; 157(11):796-807. PubMed ID: 22928173
[TBL] [Abstract][Full Text] [Related]
27. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
Di Nisio M; van Es N; Carrier M; Wang TF; Garcia D; Segers A; Weitz J; Buller H; Raskob G
J Thromb Haemost; 2019 Nov; 17(11):1866-1874. PubMed ID: 31271705
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
29. The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry.
Cohen AT; Gitt AK; Bauersachs R; Fronk EM; Laeis P; Mismetti P; Monreal M; Willich SN; Bramlage P; Agnelli G; Prefer In Vte Scientific Steering Committee And The Prefer In Vte Investigators OBOT
Thromb Haemost; 2017 Jun; 117(7):1326-1337. PubMed ID: 28405675
[TBL] [Abstract][Full Text] [Related]
30. Recurrent thromboembolism, bleeding, and mortality in Asian patients with venous thromboembolism receiving different oral anticoagulants: A nationwide analysis.
Lee MC; Liao CT; Feng IJ; Yu T; Chang WT; Shih MF; Su HC; Toh HS
Medicine (Baltimore); 2022 Sep; 101(37):e30412. PubMed ID: 36123930
[TBL] [Abstract][Full Text] [Related]
31. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
32. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
[TBL] [Abstract][Full Text] [Related]
33. Warfarin Discontinuation in Patients With Unprovoked Venous Thromboembolism: A Large US Insurance Database Analysis.
Xie L; Liu X; Phatak H; Mardekian J; Tan W; Baser O; Ramacciotti E
Am J Ther; 2016; 23(6):e1744-e1753. PubMed ID: 26214203
[TBL] [Abstract][Full Text] [Related]
34. Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population-Based Study.
Yu AYX; Malo S; Svenson LW; Wilton SB; Hill MD
J Am Heart Assoc; 2017 Oct; 6(11):. PubMed ID: 29080863
[TBL] [Abstract][Full Text] [Related]
35. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM
Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694
[TBL] [Abstract][Full Text] [Related]
36. Trends in Prevalence of Non-Valvular Atrial Fibrillation and Anticoagulation Therapy in a Japanese Region - Analysis Using the National Health Insurance Database.
Narita N; Okumura K; Kinjo T; Mikami J; Tsushima K; Takahashi R; Noro M; Hashimoto A; Sasaki T; Takaki M; Ishidoya E; Narita Y; Imai H; Ono E; Tomita H
Circ J; 2020 Apr; 84(5):706-713. PubMed ID: 32213724
[TBL] [Abstract][Full Text] [Related]
37. Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach.
Black SA; Cohen AT
Thromb Haemost; 2015 Oct; 114(4):660-9. PubMed ID: 26084864
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of new oral anticoagulants compared to those of warfarin in AF patients with cancer: a meta-analysis of randomized clinical trials and observational studies.
Chen Y; Mao M; Chang J; Yan J; Yang T; Liu Y; Luo M; Hu Y; Yang Q; Zhou L; Ma K
Eur J Clin Pharmacol; 2021 Jun; 77(6):849-857. PubMed ID: 33791828
[TBL] [Abstract][Full Text] [Related]
39. The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.
Jugrin AV; Ustyugova A; Urbich M; Lamotte M; Sunderland T
Thromb Haemost; 2015 Oct; 114(4):778-92. PubMed ID: 26272227
[TBL] [Abstract][Full Text] [Related]
40. Transition of management strategies and long-term outcomes in cancer-associated venous thromboembolism from the warfarin era to the direct oral anticoagulant era.
Chatani R; Yamashita Y; Morimoto T; Kaneda K; Mushiake K; Kadota K; Nishimoto Y; Ikeda N; Kobayashi Y; Ikeda S; Kim K; Inoko M; Takase T; Tsuji S; Oi M; Kimura T;
Eur J Intern Med; 2024 May; 123():72-80. PubMed ID: 38278660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
